March 28, 2025
Novo inks second obesity deal of the week, with Lexicon oral drug partnership worth up to $1B
Obesity, LX9851, lexicon, Mechanism (attribute)
FDA Rejects Milestone Pharmaceuticals’ Etripamil Nasal Spray for PSVT
Etripamil, Cardamyst, PSVT, FDA rejection, Complete Response Letter, manufacturing issues, Milestone Pharmaceuticals
CHMP recommends seven label expansions and one new approval, rejects Lilly Alzheimer’s drug
CHMP, Labels (device), expansions, Approved
BioAtla lays off 30% of staff, hunts out partners for ADC and cancer antibody
Staff, Partner in relationship, CAB, BioAtla, 30%
BioNTech shows off lung cancer survival data behind phase 3 push for red-hot bispecific
BNT327, BioNTech, month, BioNTech ‘s, Small cell carcinoma of lung, Pharmacotherapy
Merck’s Injectable Keytruda Shows Promising Results in Pivotal Trial
Keytruda, subcutaneous injection, intravenous formula, non-small cell lung cancer, pivotal trial, Merck
Equillium’s pivotal GvHD study of anti-CD6 antibody comes up short
United States Food and Drug Administration, itolizumab, In complete remission, day, Equillium
FDA to Decide on Merck’s Subcutaneous Keytruda in September 2025
Subcutaneous Keytruda, FDA decision, September 23, 2025, Merck & Co., cancer treatment, PDUFA date
HHS Overhaul: RFK Jr. Cuts 20,000 Jobs in Major Restructuring
Robert F. Kennedy Jr., Department of Health and Human Services (HHS), job cuts, restructuring, Administration for a Healthy America (AHA), chronic disease epidemic, efficiency, cost-saving